Vaxart, Inc..
VXRT.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Vaxart, Inc. is a clinical-stage biotechnology company primarily focused on the discovery, development, and commercialization of oral recombinant vaccines based on its VectorAdjuvant technology platform. Their main focus is on developing oral vaccines that are administered through tablets, eliminati...Show More
Better Health for All
0
No evidence available to assess Vaxart, Inc. on Better Health for All.
Fair Money & Economic Opportunity
0
Vaxart, Inc. is a clinical-stage biotechnology company focused on developing oral recombinant vaccines.
1
The company's core business does not involve offering lending, deposit, or other financial services to consumers.
2
Therefore, all Key Performance Indicators (KPIs) under the 'Fair Money & Economic Opportunity' value, which are designed to assess financial institutions, are not applicable to Vaxart's operations.
3
Fair Pay & Worker Respect
0
Vaxart's employee satisfaction, based on 25 reviews, is 3.3 out of 5 stars, which translates to 66% engagement.
1
Fair Trade & Ethical Sourcing
0
No specific, quantifiable evidence was found in the provided articles for any of the KPIs related to Fair Trade & Ethical Sourcing. The company's Code of Business Conduct and Ethics, amended May 2, 2023, outlines commitments to ethical practices, including terminating relationships with suppliers engaged in illegal or unethical human rights practices like child or forced labor, and emphasizes prompt action against violations.
1
However, the articles do not provide data on fair-trade certification, audit frequency, actual forced or child labor incidents, supply chain traceability, remediation speed metrics, the percentage of supplier contracts with ethical clauses, materials risk index, or supplier diversity spend.
2
Honest & Fair Business
-30
Vaxart has a whistleblower policy, amended and restated on May 2, 2023, which prohibits retaliation for good-faith reports of misconduct and allows anonymous reporting via a dedicated hotline.
1
The Audit Committee is responsible for developing procedures for employees to anonymously submit concerns about questionable accounting, ethical, and auditing matters, which are promptly and directly forwarded to the committee.
2
The company's Compensation Recovery Policy, adopted in October 2023, addresses accounting restatements due to material noncompliance with financial reporting requirements.
3
Vaxart's board of directors has determined that all director nominees except the President and CEO are independent, indicating approximately 75% of the board is conflict-free.
4
The company has a Code of Business Conduct and Ethics, amended May 2, 2023, which prohibits bribery and corruption in any form and mentions compliance with the U.S. Foreign Corrupt Practices Act, with monitoring by the Board and senior management.
5
However, training frequency and effectiveness metrics for this policy are not specified. Vaxart's facilities and third-party manufacturers are subject to periodic inspections by the FDA and local authorities, and regulatory agencies require extensive monitoring and auditing of clinical activities, data, and investigators during clinical development.
6
Kind to Animals
-40
Vaxart conducts preclinical animal studies for its vaccine candidates, including using hamsters and non-human primates.
1
A preclinical study for its COVID-19 vaccine candidate involved 8 hamsters per group.
2
The company states that its nonclinical laboratory tests and animal studies are conducted according to Good Laboratory Practices (GLPs) and applicable requirements for the humane use of laboratory animals, including the Animal Welfare Act.
3
This indicates compliance with legal mandates for animal welfare but does not provide evidence of a policy that goes beyond these minimum requirements or actively restricts non-essential testing.
No War, No Weapons
0
Vaxart, Inc. is a clinical-stage biotechnology company focused on developing oral vaccines for infectious diseases such as COVID-19, influenza, and norovirus.
1
The company received a $460.7 million project award from BARDA, a component of the U.S. Department of Health and Human Services, for a Phase 2b clinical trial of its oral COVID-19 vaccine candidate.
2
This funding is for public health preparedness and vaccine development, not for arms or defense contracts. There is no evidence to suggest the company's vaccine technology is dual-use with military applications, that it has any exposure to controversial weapons, or that it engages in any activities related to arms, defense, or conflict.
Planet-Friendly Business
0
No specific data on Vaxart, Inc.'s environmental performance, emissions, renewable energy use, water management, waste diversion, or any other planet-friendly business practices is available in the provided articles.
1
The articles explicitly state that sustainability data for VXRT.US is unavailable or not provided.
2
Respect for Cultures & Communities
0
No specific, concrete data points were found in the provided articles regarding Vaxart, Inc.'s performance on any of the KPIs related to Respect for Cultures & Communities. The articles provided were either general market news, unrelated company financial transactions, or led to a 404 error, none of which contained information relevant to cultural engagement, community partnerships, local investment, or cultural incident management for Vaxart, Inc.
Safe & Smart Tech
0
No evidence available to assess Vaxart, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No specific, concrete data points related to waste diversion rate, product recyclability, packaging sustainability, recycled content percentage, single-use plastic reduction, take-back program coverage, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability score, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging to product ratio, waste reduction targets, supplier waste requirements, or customer waste education were found across the provided articles. explicitly states that sustainability data is not available for VXRT.US.
1
Articles and discuss greenhouse gas emissions related to vaccine types and cold chain, but explicitly state they do not focus on zero-waste or sustainable product metrics for Vaxart.
2
Therefore, no KPIs can be scored against the 'Zero Waste & Sustainable Products' value.